摘要
目的:探讨肺腺癌患者血清微小核糖核苷酸(miRNA)-21和miRNA-4534水平变化及其与病理特征和预后的关系。方法:选取湖州市第一人民医院2018年1月至2019年1月收治的肺腺癌患者148例为观察组,另选取该院2018年1月至2019年1月健康体检者100例为对照组。采用实时荧光定量聚合酶链式反应(qRT-PCR)法测定血清miRNA-21和miRNA-4534相对表达量。比较两组血清miRNA-21和miRNA-4534相对表达量,不同病理特征肺腺癌患者血清miRNA-21和miRNA-4534相对表达量;miRAN-21高表达和miRNA-21低表达患者总生存时间;miRNA-4534高表达和miRNA-4534低表达患者总生存时间。结果:观察组血清miRNA-21相对表达量(3.27±0.87)和miRNA-4534相对表达量6.74±1.56均高于对照组(1.00±0.01、1.02±0.02)(t=20.07、36.64,均P<0.05)。不同性别、年龄、体质量指数、肿瘤部位和肿瘤直径血清miRNA-21和miRNA-4534相对表达量比较,差异均无统计学意义(均P>0.05);Ⅲ~Ⅳ期肺腺癌患者血清miRNA-21相对表达量(4.45±1.05)高于Ⅰ~Ⅱ期1.92±0.53,且淋巴结转移4.97±1.28高于无淋巴结转移1.34±0.60(t=17.53、23.48,均P<0.05)。血清miRNA-4534相对表达量Ⅲ~Ⅵ期(8.97±1.85)高于Ⅰ~Ⅱ期(4.48±1.09),且淋巴结转移9.65±1.35高于无淋巴结转移3.78±0.91(t=17.17、30.59,P<0.05)。miRNA-21高表达患者总生存时间[(18.37±4.35)个月]短于miRNA-21低表达患者[(29.93±3.24)个月](t=18.45,P<0.05)。miRNA-4534高表达患者总生存时间[(17.56±4.21)个月]短于miRNA-4534低表达患者[(30.43±3.63)个月](t=19.97,P<0.05)。结论:肺腺癌患者血清miRNA-21和miRNA-4534高表达,且与TNM分期、淋巴结转移及预后密切相关。
Objective To investigate the changes in serum miRNA-21 and miRNA-4534 levels in patients with lung adenocarcinoma and their relationships with pathological characteristics and prognosis.Methods A total of 148 patients with lung adenocarcinoma who received treatment in the First People's Hospital of Huzhou from January 2018 to January 2019 were included in the observation group.An additional 100 healthy controls who concurrently received physical examinations were included in the control group.The relative expression of serum miRNA-21 and miRNA-4534 was measured using real-time fluorescence quantitative PCR.The relative expression of serum miRNA-21 and miRNA-4534 was compared between the two groups.The relative expression of serum miRNA-21 and miRNA-4534 was compared between patients with different pathological characteristics.Total survival time was compared between patients with high and low miRAN-21 expression and between patients with high and low miRNA-4534 expression.Results The relative expression of miRNA-21 and miRNA-4534 in the observation group was 3.27±0.87 and 6.74±1.56,respectively,which was significantly higher than 1.00±0.01 and 1.02±0.02 in the control group(t=20.07,36.64,both P<0.05).There was no significant difference in the relative expression of miRNA-21 and miRNA-4534 between different genders,ages,body mass index values,tumor regions,and tumor diameters(all P>0.05).The relative expression of serum miRNA-21 in patients with stageⅢ-Ⅳlung adenocarcinoma was 4.45±1.05,which was significantly higher than 1.92±0.53 in patients with stageⅠ-Ⅱlung adenocarcinoma.The relative expression of serum miRNA-21 in patients with lymph node metastasis was higher than that in patients without lymph node metastasis(4.97±1.28 vs.1.34±0.60,t=17.53,23.48,both P<0.05).The relative expression of miRNA-4534 in patients with stageⅢ-Ⅳlung adenocarcinoma was higher than that in patients with stageⅠ-Ⅱlung adenocarcinoma(8.97±1.85 vs.4.48±1.09,t=17.17,P<0.05).The relative expression of miRNA-4534 in patients with lymph node metastasis was higher than that in patients without lymph node metastasis(9.65±1.35 vs.3.78±0.91,t=30.59,P<0.05).The total survival time in patients with high miRNA-21 expression was shorter than that in patients with low miRNA-21 expression[(18.37±4.35)months vs.(29.93±3.24)months,t=18.45,P<0.05].The total survival time in patients with high miRNA-4534 expression was shorter than that in patients with low miRNA-4534 expression[(17.56±4.21)months vs.(30.43±3.63)months,t=19.97,P<0.05].Conclusion Patients with lung adenocarcinoma have high expression of miRNA-21 and miRNA-4534 in the serum,which is closely related to the tumor-node-metastasis stage,lymph node metastasis,and prognosis.
作者
贾丹
谢艳萍
Dan Jia;Yanping Xie(Department of Respiratory Medicine,the First People's Hospital of Huzhou,Huzhou 313000,Zhejiang Province,China)
出处
《中国基层医药》
CAS
2023年第1期11-15,共5页
Chinese Journal of Primary Medicine and Pharmacy
基金
浙江省科技计划(2017C37103)。
关键词
腺癌
细支气管肺泡
核糖核苷酸类
基因表达
聚合酶链反应
肿瘤分期
淋巴转移
预后
Adenocarcinoma,bronchiolo-alveolar
Ribonucleotides
Gene expression
Polymerase chain reaction
Neoplasm staging
Lymphatic metastasis
Prognosis
